Every 5 to 6 years, international and national guidelines provide updated recommendations for the standard management of hypertension in adults. Thus, within the last 18 months, societies from Excellence) published their new guidelines. Despite the fact that all of them are supposedly based on the most recent clinical evidence, there are always some discrepancies between recommendations due to different interpretation of clinical trials. The purpose of the present review is to discuss 6 issues that have generated some controversies, namely, the definition of hypertension, identification of patients who should be treated, target blood pressure, pertinence of reducing salt intake, mono-or combination therapy as first-line treatment, and the role of renal denervation in resistant hypertension.
diastolic BP higher than 115 mm Hg and to con sider therapy in those with diastolic BP high er than 90 mm Hg depending on their cardio vascular risk. 4 In the same decade, the first guidelines for the management of hyperten sion were issued first by the World Health Or ganization (WHO) and the International Soci ety of Hypertension (ISH), and thereafter by the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pres sure with the objective to help physicians in their clinical decisions. 5 The guidelines were written by hypertension experts and updated periodically. Until 2003, the ESH and ESC en dorsed the WHO / ISH guidelines, but thereaf ter it was believed that these guidelines might not be representative because of the heteroge nous accesses to health care, drug therapies, and economic resources of the countries. Therefore, they started to publish their own guidelines in 2003, introducing progressively evidence based criteria. Simultaneously, several coun tries started to publish their own national rec ommendations. 6 The latter were sometimes, but not always, in accordance with the inter national guidelines coming from the United Introduction Hypertension is the main risk factor of cardiovascular diseases worldwide, affecting more than 1 billion people globally. Reducing blood pressure (BP) in patients with hypertension is the most effective way to low er the mortality rates and target organ damag es associated with hypertension. 1 Today, these 2 allegations are well accepted in the medi cal community, but this has not always been the case. Indeed, in the midst of the 20th cen tury, many physicians deemed arterial hyper tension a compensatory mechanism that did not deserve any treatment, whereas others were proposing drug treatments for those with an el evated BP without a strong support of clinical trials. This was probably the first important con troversy in the management of essential hyper tension. In the 1960s and 1970s, the first ran domized controlled trials conducted by the Vet erans Administration Cooperative Study Group confirmed the benefits of treating patients with elevated diastolic BP. 2,3 Consequently, in 1977, the first Joint National Committee on Detec tion, Evaluation, and Treatment of High Blood Pressure published a strict recommendation to treat any patient with hypertension with and a diastolic BP of less than 80 mm Hg have an elevated BP. This major modification has generated many negative reactions for sever al reasons. Firstly, it increased by almost 15% the number of patients with hypertension in the population; secondly, it also increas es the percentage of treated patients with un controlled hypertension; and, thirdly, it rais es substantially the number of patients with low cardiovascular risk needing clinical man agement by general practitioners with the risk of inducing more adverse effects than clinical benefits. Interestingly, in the United States, the American Academy of Family Physicians and the American College of Physicians rejected this modification. Thus, we face a situation in which various definitions of hypertension ex ist, which might have direct consequences for the management of the disorder. 11 The main reason why the ACC / AHA guide lines committee changed the definition of hy pertension is the results of the SPRINT (Systol ic Blood Pressure Intervention Trial) published in 2015. 12 In this trial, targeting a systolic BP of less than 120 mm Hg, as compared with less than 140 mm Hg, resulted in lower rates of fa tal and nonfatal major cardiovascular events and all cause mortality. Moreover, the bene fits of reaching the lower target were also ob served in the elderly. 13 However, the method used to measure office BP in SPRINT was a ma jor issue. Indeed, in contrast to all previous clin ical trials on hypertension, SPRINT investiga tors used a different methodology combining an automated device with measurements done in a quiet room unattended or unobservedthat is, without an observer being present in the room. 14 6, 17 This seems reasonable as long as office BP is mea sured using either auscultatory or oscillometric devices in the presence of a physician or a nurse. Physicians could apply the ACC / AHA defini tion only if they modify their habits and start measuring BP according to the SPRINT proto col, that is, with an automated device in a quiet room and without any healthcare professional in the room (unattended).
States or Europe, leading to controversies with regard to the management of patients with hy pertension. In this respect, the recently pub lished guidelines by the ESC / ESH 7 in Europe and by the ACC / AHA 8, 9 in the United States, and even more recently, the 2019 NICE guide lines in Great Britain 10 did not avoid the contro versy, with some substantial differences gener ating animated discussion. The purpose of this article is to discuss some of the recent contro versies in the diagnosis and management of hy pertension in adults according to the most re cent recommendations.
Definition of hypertension: is >140/90 mm Hg still correct? The major current controver sy concerns the definition of hypertension. Hypertension in adults is defined as a BP of 140/90 mm Hg or higher with a special con sideration for elderly patients with isolat ed systolic hypertension defined as a systol ic BP of 140 mm Hg or higher but a diastolic BP of less than 90 mm Hg. These definitions have been accepted and applied worldwide for decades. In 2018, the ACC/AHA guidelines changed this definition putting the cut off point between normotension and hypertension at 130/80 mm Hg 8,9 (TABLe 1). In addition, those with a systolic BP between 120 and 129 mm Hg experienced hypotensive episodes and worsen ing of renal function more frequently. 12 Lastly, such a low target might increase the number of consultations needed to manage patients with hypertension and lead to overload of many gen eral practitioners.
Therefore, it appears more reasonable to apply the target strategy from the ESC / ESH guide lines, 7 which recommend a range of targets to be achieved in 2 steps. The first is to bring BP below 140/90 mm Hg in all hypertensive pa tients. Then, BP can be lowered further to 130 to 140 mm Hg in most patients depending on their age, level of cardiovascular risk, tolerance to hy pertensive therapy, and presence or absence of concomitant diseases. is based, again, on the results of the SPRINT trial and some, but not all, meta analyses have raised many issues. First, this low target will be difficult to achieve in many patients if one con siders that today less than 50% of treated pa tients with hypertension achieve a target BP of less than 140/90 mm Hg. Therefore, this may be come discouraging for both patients and physi cians. Moreover, there is no evidence from ran domized controlled trials to support a diastolic BP of less than 80 mm Hg. In addition, in some patients, like the elderly, a more intensive treat ment to reach low targets may be rather harm ful. Indeed, in the SPRINT trial patients ran domized to the 120 mm Hg systolic BP target Therefore, they concluded that inaccurate es timates of sodium intake (with formulas based on a spot urine tests) cannot be used in asso ciation studies, as variables used in the for mulas per se seem to be related to mortality independent of sodium. 29 Whether this find ing will close the dispute is unknown; howev er, it is unlikely. Nevertheless, in most countries, salt con sumption is high. The estimated mean level of global sodium consumption was 3.95 g per day (or 10 g sodium chloride per day) in a study by Mozaffarian et al, 24 but with regional mean sodi um levels ranging from 2.18 to 5.51 g per day. In this study, countries from Central and Eastern Europe had the highest sodium intakes. Thus, it is wise to recommend a general reduction of sodi um intake in these populations, including Polish populations. At this point it is useful to remem ber that in patients with hypertension, lowering salt intake is beneficial in several aspects: not only does it lowers BP and cardiovascular events but also increases the antihypertensive efficacy of RAS blockers and diuretics and lowers micro albuminuria. At the 2019 ESC meeting in Paris, Dr Jaime Miranda from Lima presented the re sults of their prospective study in Peru, in which they replaced the normal sodium chloride with a salt substitute containing 75% sodium and 25% potassium in the households of 6 Peruvian vil lages. 30 The salt substitution induced a modest decrease in BP in the population, but the most striking result was that it reduced the likeli hood of developing hypertension by 51% com pared with normal salt (hazard ratio, 0.49; 95% confidence interval, 0.34-0.71; P <0.001). 31 Thus, these data suggest that lowering salt intake may prevent the development of new cases of hyper tension. Therefore, even though there may still be some controversy on the pertinence of reduc ing salt intake to 5 to 6 g a day, salt reduction appears to be a wise recommendation, at least in patients with hypertension.
Resistant hypertension and renal denerva tion: still alive? The development of device therapies such as renal denervation (RDN), baro reflex activation therapy, and endovascular baro reflex modulation has stimulated the clinical in terest and research in the field of resistant hy pertension. Indeed, these devices were original ly designed to improve the management of pa tients with severe uncontrolled hypertension and this promoted much research on the prev alence and clinical characteristics of resistant hypertension.
Several surveys have been conducted to de termine the prevalence of resistant hyperten sion. [32] [33] [34] [35] Interestingly, large discrepancies were found in these studies with prevalence rang ing from 5% to 30%. In fact, after excluding the cases of pseudo resistant hypertension due the ESC / ESH guidelines recommend to start an tihypertensive treatment with a single pill com bination of 2 drug classes, that is, a renin-an giotensin system (RAS) blocker combined with a diuretic or a calcium channel blocker. The sec ond set consists in prescribing a single pill triple combination with a RAS blocker, diuretic, and calcium antagonist. This more aggressive initi ation of therapy should enable to control BP in 50% to 60% of patients after the first prescrip tion of a single pill. Yet, the use of a monothera py as the first step is not completely abandoned but it is reserved to frail, very elderly patients or to younger patients with a modest elevation of BP. This new therapeutic approach was general ly well received but its implementation may be challenging in some countries, as dual and tri ple single pill combinations are not universally available or reimbursed.
Lifestyle changes: should sodium intake be reduced? To what level? Physiological ly, sodium is one of the main determinants of BP. Several epidemiological surveys have demonstrated that the higher the salt intake in populations, the higher the BP and the risk of developing hypertension with age. 20 -24 There is also a relationship between sodium intake and the risk of death and cardiovas cular events. 20,24 -27 However, some investiga tors found a linear correlation between sodium intake and cardiovascular events, 25,26 where as others reported an increased risk of death and cardiovascular events at higher as well as at lower estimated levels of sodium intake, suggesting a U shaped relationship. 27,28 There fore, the authors of these latter observations do not support the recommendations made by the WHO, AHA, or ESC / ESH to reduce sodium intake in populations to 1.5 to 2.0 g sodium per day or 5 g sodium chloride per day. These ap parently contradictory results caused a consid erable controversy in the cardiovascular com munity, some supporting a general reduction in salt intake in populations and others sug gesting no changes. For many years, the rea sons for the discrepancy were not well under stood except for the fact that spot urine sam ples rather than 24hour urine collections were used to estimate sodium intake in studies re porting a U shaped relationship. Very recent ly, He et al 29 reanalyzed the Trials of Hyperten sion Prevention follow up data. They calculat ed sodium intake using the measured 24hour urinary sodium excretion as well as the esti mations from spot sodium concentrations us ing the Kawasaki, Tanaka, and INTERSALT (In ternational Cooperative Study on Salt) formu las. Their analysis suggested that a U shaped relationship is due to an artefact associated with the use of spot urine samples, which take into account sodium as well as creatinine. 29 according to the 24hour ambulatory BP data, the BP lowering effect of RDN appears to be modest, equivalent to the efficacy of 1 anti hypertensive drug. Moreover, the response to RDN remains unpredictable and it is almost im possible to define good candidates for RDN a priori. Thus, taken together, these results con firm that RDN lowers BP but, at the present time, this approach cannot be recommended for routine use. However, it might be suggest ed to patients with severe hypertension despite a high number of prescribed drugs or to non adherent patients who refuse antihypertensive drugs. However, in many of these patients, RDN per se will not be sufficient to control BP ade quately. Several studies are still ongoing and physicians may have to wait for a better posi tioning of this approach in the management of patients with hypertension.
Conclusion This article briefly discusses 6 current major points of controversy from the field of arterial hypertension. On the last pages of the 2018 ESC / ESH hypertension guidelines, there is a list of 26 topics for which there are major gaps in evidence and addition al studies are needed. 7 Each of these topics could represent a matter of controversial de bate. In the absence of sufficient evidence, phy sicians have to make decision according to their own experience in the best interest of their patients. In this respect, the best interest of a patient with hypertension is often to have a well controlled BP. to nonadherence to drug therapy and white coat hypertension, the prevalence of true re sistant hypertension was much lower, below 5% in the general population and slightly high er in hypertension centers, where complicated cases are referred. 36 The second observation is that many patients with resistant hyperten sion can actually be conrolled using the pre scription of spironolactone as the fourthline therapy after diuretics, calcium antagonists, and RAS blockers. [37] [38] [39] [40] Thus, the real need for an interventional therapy decreased signifi cantly as more precise data on resistant hy pertension were gathered.
The initial clinical and experimental studies using radiofrequency RDN to reduce BP in pa tients with resistant hypertension were quite promising, 41, 42 but the enthusiasm faded af ter the publication of the negative results of SYMPLICITY HTN3, 43 which lead to a dras tic reduction in the number of procedures per formed around the world. Nevertheless, some device companies did not stop their programs and even started new ones with revised ob jectives. New goals were to demonstrate that RDN indeed lowers BP in other groups of pa tients, to refine the technology in order to apply the denervation more distally in renal arteries, and to reduce the variability of the response to RDN improving the selection of patients who could benefit from the therapy. Two clinical programs should be cited, that is, the SPYRAL and the RADIANCE study programs. These pro grams addressed different populations, such as treatmentnaive patients with hypertension, and new technologies, such as ultrasounds, as reviewed recently by Lobo et al. 44 Several of these studies confirmed the antihypertensive efficacy of RDN when compared with a sham procedure, as illustrated in FIgURe 1. [45] [46] [47] In addi tion to these studies, several registries were created to collect the multiple local experienc es. The first results of these registries actually support the conclusions of the trials. 44 However, 
